Spyre Therapeutics
SYRE
198 hedge funds and large institutions have $4.16B invested in Spyre Therapeutics in 2026 Q1 according to their latest regulatory filings, with 58 funds opening new positions, 67 increasing their positions, 49 reducing their positions, and 11 closing their positions.
952% more call options, than puts
Call options by funds: $16.4M | Put options by funds: $1.55M
427% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 11
67% more funds holding in top 10
Funds holding in top 10: 6 → 10 (+4)
57% more capital invested
Capital invested by funds: $2.65B → $4.16B (+$1.51B)
37% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 49
29% more funds holding
Funds holding: 153 → 198 (+45)
0.91% more ownership
Funds ownership: 104.36% → 105.27% (+0.91%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$34.5M |
| 2 |
CP
Caligan Partners
New York
|
+$33.1M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$30.5M |
| 4 |
PA
Perceptive Advisors
New York
|
+$26.9M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
+$18.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$65.8M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
-$26.5M |
| 3 |
DM
Deerfield Management
New York
|
-$23.3M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$21.7M |
| 5 |
CC
Commodore Capital
New York
|
-$17.9M |
SYRE Hedge Fund Activity: Q1 2026 in Review
198 of the 8,184 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q1 2026, worth a combined $4.16B — up 57% from $2.65B a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new SYRE positions and 11 closed out — a net gain of 47 holders — while 67 added to existing stakes and 49 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $34.5M. The largest seller was Capital International Investors, cutting an estimated $65.8M.
- 198 institutional investors held Spyre Therapeutics (SYRE) as of Q1 2026, up from 153 in Q4 2025.
- Funds reported $4.16B of Spyre Therapeutics stock for Q1 2026, up 57% quarter-over-quarter.
- 58 funds opened new Spyre Therapeutics positions in Q1 2026 and 11 closed out, a net change of +47 holders.
- The largest Spyre Therapeutics buyer in Q1 2026 was JP Morgan Chase, an estimated $34.5M added.
- The largest Spyre Therapeutics seller in Q1 2026 was Capital International Investors, an estimated $65.8M sold.
Based on aggregated 13F filings for Q1 2026.